India’s clinical acumen and quality of healthcare infrastructure designated to conduct human studies are two key parameters which have impressed US FDA officials. The country is an important destination for clinical trials not just for a patient pool but the expertise which it has armed with in terms of personnel and hospital sites, said Dr Steve Wilson, director of Division Biometrics III, Centre for Drug Evaluation and Research, US FDA.
The details can be read here.
No comments:
Post a Comment